Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study.
MRI
Predictive factors
Ulipristal acetate
Uterine fibroids
Journal
Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
22
01
2019
revised:
31
05
2019
accepted:
11
07
2019
pubmed:
9
10
2019
medline:
20
9
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
Can patient and/or uterine fibroid characteristics predict the volume reduction of fibroids under ulipristal acetate (UPA) treatment? This was a monocentric observational prospective cohort study of women with symptomatic fibroids who were willing to undergo surgery after a 3-month treatment of daily 5 mg doses of UPA. Patients underwent magnetic resonance imaging before and after treatment, and the volumes of the three largest fibroids were assessed. The reduction in volume was assessed qualitatively: fibroids decreasing in volume were considered to be 'responsive' to treatment, and fibroids that were stable or increased in volume were considered to be 'non-responsive'. Comparisons were made of patient (age and body mass index) and fibroid (initial volume, number and location) characteristics between fibroids that were responsive and non-responsive to UPA treatment. Fifty-three women were included in the final analysis and 116 fibroids were measured. The initial number and initial volume of the fibroids were statistically associated with the response to UPA treatment (adjusted odds ratio [OR] 0.645, 95% confidence interval [CI] 0.461-0.903, P = 0.0115 for number of fibroids, and adjusted OR 1.447, 95% CI 1.063-1.970, P = 0.0195 for initial volume, with a log-linear relationship). Submucosal fibroids had a higher response rate to treatment (i.e. a decrease in volume) than intramural fibroids (21/25 [84.0%] versus 15/28 [53.6%]; P = 0.0490; adjusted OR 4.478, 95% CI 1.007-19.918). The location, initial volume and number of fibroids may allow prediction of the outcome of a single 3-month treatment course of daily 5 mg doses of UPA in terms of reduction in volume before surgery.
Identifiants
pubmed: 31594689
pii: S1472-6483(19)30661-3
doi: 10.1016/j.rbmo.2019.07.028
pii:
doi:
Substances chimiques
Norpregnadienes
0
ulipristal acetate
YF7V70N02B
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
795-801Informations de copyright
Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.